Federal health officials have approved an experimental drug to treat psychotic delusions and behaviors that often afflict patients with Parkinson's disease, the debilitating movement disorder.
Valeant Pharmaceuticals resolved its default on some of its $30 billion in debt by finally filing its long-overdue U.S. financial report for 2015 on Friday. The badly tarnished Canadian drugmaker also announced a slate of mostly new nominees for elections to its board in June.
Gilead Sciences' earnings tumbled more than 17% in the first quarter as steeper discounts and rebates on its blockbuster hepatitis C drugs cut into sales.
AbbVie on Thursday reported a boost in first-quarter profit on higher sales of the drug Humira and said it will buy cancer drug developer StemCentrx for more than $5.8 billion.
Drugmaker Sanofi says it has made a $9.3 billion bid for San Francisco pharmaceutical firm Medivation, part of the firm's effort to expand its portfolio of cancer treatments.
Just weeks after the collapse of Pfizer's controversial deal to buy fellow drugmaker Allergan and move its headquarters to Ireland, company executives faced sharp criticism from shareholders at their annual meeting.
Pfizer subsidiary Wyeth and the government have finalized a $784.6 million settlement over allegations that Wyeth hid drug discounts to avoid paying Medicaid millions of dollars in rebates.
The outgoing CEO of embattled drugmaker Valeant Pharmaceuticals will tell lawmakers Wednesday that he was "too aggressive" and made mistakes in significantly hiking prices for several critical medicines, according to testimony provided to the Associated Press.
Lawmakers accused drugmaker Valeant Pharmaceuticals of gouging patients to reward Wall Street investors at a hearing Wednesday focused on the embattled drugmaker's pricing tactics.
The House Judiciary Committee on Wednesday took an election-year swipe at the nation's growing drug addiction problem, approving federal grants that would bolster state and local efforts against the abuse of opioid painkillers.
Senate lawmakers investigating price hikes by the embattled drugmaker Valeant Pharmaceuticals will also question one of the company's leading investors, hedge fund manager William Ackman. A Senate committee holds its third meeting on drug prices on Wednesday.
Swiss pharmaceuticals maker Novartis says net income from continued operations fell 13% in the first quarter as generic competition cut into sales of Gleevec, one of the first very effective cancer medicines.